TITLE

CLINICAL CONSULTATION. Commonly prescribed medications and potential false-positive urine drug screens

AUTHOR(S)
Brahm, Nancy C.; Yeager, Lynn L.; Fox, Mark D.; Farmer, Kevin C.; Palmer, Tony A.
PUB. DATE
August 2010
SOURCE
American Journal of Health-System Pharmacy;8/15/2010, Vol. 67 Issue 16, p1344
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The implications of potential false-positive urine drug screen (UDS) results for patients receiving commonly prescribed medications were evaluated. Summary. A comprehensive literature review was conducted to identify false-positive UDSs associated with all clinic formulary medications, as well as common nonprescription medications. The references of each report describing a medication whose use was associated with false-positive UDS results were also reviewed. If a class effect was suspected, additional agents in the category were searched. A total of 25 reports of false-positive UDS results were identified. Categories of medications included antihistamines, antidepressants, antibiotics, analgesics, antipsychotics, and nonprescription agents. Reports of false-positive results were found for the following formulary and nonprescription medications: brompheniramine, bupropion, chlorpromazine, clomipramine, dextromethorphan, diphenhydramine, doxylamine, ibuprofen, naproxen, promethazine, quetiapine, quinolones (ofloxacin and gatifloxacin), ranitidine, sertraline, thioridazine, trazodone, venlafaxine, verapamil, and a nonprescription nasal inhaler. False-positive results for amphetamine and methamphetamine were the most commonly reported. False-positive results for methadone, opioids, phencyclidine, barbiturates, cannabinoids, and benzodiazepines were also reported in patients taking commonly used medications. The most commonly used tests to screen urine for drugs of abuse are immunoassays, even though false-positive results for drugs of abuse have been reported with a number of these rapid-screening products. Results from such tests should be confirmed using additional analytical methods, including gas chromatography--mass spectrometry. Conclusion. A number of routinely prescribed medications have been associated with triggering false-positive UDS results. Verification of the test results with a different screening test or additional analytical tests should be performed to avoid adverse consequences for the patients.
ACCESSION #
52947482

 

Related Articles

  • Anatomy of an Epidemic: Psychiatric Drugs and the Astonishing Rise of Mental Illness in America. Whitaker, Robert // Ethical Human Psychology & Psychiatry;Spring2005, Vol. 7 Issue 1, p23 

    Over the past 50 years, there has been an astonishing increase in severe mental illness in the United States. The percentage of Americans disabled by mental illness has increased fivefold since 1955, when Thorazine--remembered today as psychiatry's first "wonder" drug--was introduced into the...

  • Discriminative stimulus properties of the atypical antipsychotic clozapine and the typical antipsychotic chlorpromazine in a three-choice drug discrimination procedure in rats. Porter, Joseph H.; Prus, Adam J.; Vann, Robert E.; Varvel, Stephen A. // Psychopharmacology;Feb2005, Vol. 178 Issue 1, p67 

    Rationale: The atypical antipsychotic drug (APD) clozapine elicits a robust discriminative cue that is generally selective for other atypical APDS in two-choice drug discrimination (DD) procedures. Objectives: The present study determined whether a three-choice DD procedure with the atypical APD...

  • From Chlorpromazine to Clozapine -- Antipsychotic Adverse Effects and the Clinician's Dilemma. Abidi, Sabina; Bhaskara, Sreenivasa M. // Canadian Journal of Psychiatry;Dec2003, Vol. 48 Issue 11, p749 

    The pharmacotherapy of schizophrenia remains an ongoing challenge for researchers and clinicians alike. Current medications remain suboptimal to effectively treat this illness despite the recent surge of what are considered to be better antipsychotics: the atypicals. The atypicals cause fewer...

  • Simultaneous Determination of 25 Common Pharmaceuticals in Whole Blood Using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry. Nielsen, Marie Katrine Kiose; Johansen, Sys Stybe // Journal of Analytical Toxicology;Sep2012, Vol. 36 Issue 7, p497 

    The article discusses the development of an ultra-performance liquid chromatography-tandem mass spectrometry method for quantifying 25 pharmaceuticals in blood. These pharmaceuticals consist the most frequently detected drugs in a forensic laboratory with properties such as antidepressants,...

  • Monitoring the Safe Use of Clozapine: A Consensus View from Victoria, Australia. Berk, Michael; Fitzsimons, Joanna; Lambert, Timothy; Pantelis, Christos; Kulkarni, Jayashri; Castle, David; Ryan, Elizabeth W.; Jespersen, Sean; McGorry, Pat; Berger, Gregor; Kuluris, Bill; Callaly, Tom; Dodd, Seetal // CNS Drugs;2007, Vol. 21 Issue 2, p117 

    Clozapine is an important antipsychotic agent that has a unique profile of clinical benefits, but that has also been associated with several serious and potentially life-threatening safety concerns. In order to minimise the impact of haematological adverse events, health professionals treating...

  • Unlocking psychosis. Turner, Trevor // BMJ: British Medical Journal (International Edition);Jan2007 Supplement, Vol. 334, ps7 

    This article discusses the rise of psychopharmacology with experimentation with antihistamines in 1949. The drug, chlorpromazine, was synthesized from the phenothiazine group of the antihistamines. Clinical trials with the drugs produced psychiatric wards that were transformed and contacts with...

  • Are antihistamines safe? Reinhart, Richard O.; Gilbert, Gordon A. // Business & Commercial Aviation;Apr98, Vol. 82 Issue 4, p48 

    Focuses on the safety regulations of antihistamines, used in a variety of over the counter (OTC) medications. Information on the side effects; Insight to a study carried out; Results of the study.

  • Claritin Receives OTC Status.  // Chemical Market Reporter;12/2/2002, Vol. 262 Issue 20, p4 

    Reports on the U.S. Food and Drug Administration's approval of the over-the-counter sales of Claritin antihistamine from Schering-Plough Corp. Non-drowsy allergy relief offered by Claritin; Drug safety; Costs.

  • Best Pharmacy Picks for Whatever Ails You.  // U.S. News Digital Weekly;6/27/2014, Vol. 6 Issue 26, p12 

    Statistics are given regarding the over-the-counter recommendations for different pharmacy products including acid reducers, acne products, antibiotics, antihistamines and pain relievers.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics